Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) have received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $43.00.

A number of analysts have recently issued reports on LYEL shares. Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Needham & Company LLC restated a “buy” rating and set a $44.00 price objective on shares of Lyell Immunopharma in a research report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $34.00 target price on shares of Lyell Immunopharma in a research report on Monday, June 15th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. ARCH Venture Management LLC increased its position in Lyell Immunopharma by 51.5% during the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after buying an additional 938,438 shares during the period. GSK plc bought a new stake in shares of Lyell Immunopharma in the fourth quarter valued at about $46,560,000. MWG Caph Ltd bought a new stake in shares of Lyell Immunopharma in the fourth quarter valued at about $31,030,000. Vanguard Group Inc. grew its stake in shares of Lyell Immunopharma by 76.0% in the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after acquiring an additional 336,378 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares in the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Stock Down 4.1%

LYEL opened at $13.32 on Friday. Lyell Immunopharma has a 12-month low of $9.24 and a 12-month high of $45.00. The business has a 50 day moving average of $14.75 and a 200-day moving average of $20.44. The stock has a market cap of $326.34 million, a price-to-earnings ratio of -0.97 and a beta of -0.06.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%.The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. As a group, analysts expect that Lyell Immunopharma will post -7.87 earnings per share for the current year.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.